Jeff Fairman - Sep 2, 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
VP, Research
Signature
Jeff Fairman, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Sep 2, 2022
Transactions value $
-$146,583
Form type
4
Date filed
9/7/2022, 04:37 PM
Previous filing
Aug 5, 2022
Next filing
Oct 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Tax liability -$13.7K -519 -2.94% $26.38 17.1K Sep 2, 2022 Direct F1
transaction PCVX Common Stock Sale -$124K -4.66K -1.52% $26.54 302K Sep 6, 2022 By Fairman Family Trust F2, F3
transaction PCVX Common Stock Sale -$9.12K -336 -0.11% $27.14 301K Sep 6, 2022 By Fairman Family Trust F2, F4
holding PCVX Common Stock 50K Sep 2, 2022 By AF 2020 Irrevocable Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
F2 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $26.04 to $27.075. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. The shares were sold at prices ranging from $27.09 to $27.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.